Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • Heme · CLL, LymphomaRecruitingPhase 3NCT07321652

    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    Alliance for Clinical Trials in Oncology · 261 locations · Updated 2026-11-03

  • Heme · CLL, LymphomaRecruitingPhase 3NCT06943872

    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

    BeOne Medicines · 195 locations · Updated 2026-10-23

  • Heme · ALL, LymphomaNot yet recruitingPhase 3NCT07774377

    Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma

    First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-08-19

  • Heme · LymphomaNot yet recruitingPhase 3NCT07511114

    A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping

    Ruijin Hospital · 1 locations · Updated 2026-04-06

  • Heme · LymphomaRecruitingPhase 3NCT07300514

    Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

    Fudan University · 1 locations · Updated 2026-03-31

  • Heme · ALL, LymphomaRecruitingPhase 2 / Phase 3NCT07502118

    NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

    Health Institutes of Turkey · 4 locations · Updated 2026-03-30

  • Heme · ALL, LymphomaRecruitingPhase 2 / Phase 3NCT06855810

    Newly-diagnosed Pediatric T-cell ALL Protocol

    Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2025-08-26

  • Heme · LymphomaNot yet recruitingPhase 2NCT07944651

    Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure

    Tianjin Medical University Cancer Institute and Hospital · 1 locations · Updated 2026-11-18

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07734038

    Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    Kerry Rogers · 1 locations · Updated 2026-11-09

  • Heme · LymphomaNot yet recruitingPhase 2NCT07517705

    MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

    University of Nebraska · 1 locations · Updated 2026-11-06

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07582159

    Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    City of Hope Medical Center · 2 locations · Updated 2026-11-06

  • Heme · LymphomaNot yet recruitingPhase 2NCT07799220

    A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma

    Memorial Sloan Kettering Cancer Center · 7 locations · Updated 2026-11-04

  • Heme · LymphomaRecruitingPhase 2NCT06500273

    Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    Allogene Therapeutics · 86 locations · Updated 2026-10-30

  • Heme · CLL, LymphomaRecruitingPhase 2NCT03516617

    Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Mayo Clinic · 3 locations · Updated 2026-10-26

  • Heme · CLL, LymphomaRecruitingPhase 2NCT04941716

    Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

    Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-23

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07887061

    Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-21

  • Heme · LymphomaRecruitingPhase 2NCT07021989

    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

    Michael Spinner, MD · 6 locations · Updated 2026-10-20

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07557056

    Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Jennifer Woyach · 1 locations · Updated 2026-10-15

  • Heme · LymphomaRecruitingPhase 2NCT03758989

    A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

    University of Rochester · 1 locations · Updated 2026-10-13

  • Heme · CLL, LymphomaRecruitingPhase 1 / Phase 2NCT05791409

    Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

    Stichting Hemato-Oncologie voor Volwassenen Nederland · 29 locations · Updated 2026-10-05

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06514794

    A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

    Allotera Therapeutics · 18 locations · Updated 2026-09-28

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT04544592

    UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

    University of Colorado, Denver · 1 locations · Updated 2026-09-14

  • Heme · CLL, LymphomaRecruitingPhase 2NCT04169737

    Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-09-10

  • Heme · LymphomaRecruitingPhase 2NCT06745076

    Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

    University of Washington · 6 locations · Updated 2026-09-09

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT07070219

    A Study of CTD402 in T-ALL/LBL Patients

    Imviva Bio · 9 locations · Updated 2026-08-19

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06849713

    Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

    Massachusetts General Hospital · 2 locations · Updated 2026-08-11

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06390319

    Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

    St. Jude Children's Research Hospital · 4 locations · Updated 2026-08-10

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07744750

    Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma

    Changzhou No.2 People's Hospital · 1 locations · Updated 2026-08-06

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07738887

    Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

    The Lymphoma Academic Research Organisation · 29 locations · Updated 2026-07-31

  • Heme · CLL, LymphomaRecruitingPhase 1 / Phase 2NCT07609862

    A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies

    Guangzhou Lupeng Pharmaceutical Company LTD. · 1 locations · Updated 2026-07-30

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06533748

    Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

    St. Jude Children's Research Hospital · 3 locations · Updated 2026-07-16

  • Heme · LymphomaRecruitingPhase 2NCT07316010

    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-06-30

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07671378

    A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

    The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2026-06-26

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 2NCT03314974

    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06544785

    Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    PETHEMA Foundation · 19 locations · Updated 2026-06-25

  • Heme · LymphomaRecruitingPhase 2NCT07507318

    Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

    Rong Tao · 1 locations · Updated 2026-06-18

  • Heme · LymphomaRecruitingPhase 2NCT06954805

    Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

    Jennifer Amengual · 2 locations · Updated 2026-05-27

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT05480449

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

    Stephan Grupp MD PhD · 1 locations · Updated 2026-05-26

  • Heme · ALL, LymphomaRecruitingPhase 2NCT07566377

    Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    Memorial Sloan Kettering Cancer Center · 1 locations · Updated 2026-05-14

  • Heme · LymphomaRecruitingPhase 1 / Phase 2NCT07225985

    Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

    Fred Hutchinson Cancer Center · 1 locations · Updated 2026-05-11

Showing 1–40 of 110. Older studies

More hematologic trials (68) that list MRD only as a secondary endpoint
  • Heme · CLL, LymphomaRecruitingPhase 3NCT05947851

    A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    Merck Sharp & Dohme LLC · 107 locations · Updated 2026-11-17

  • Heme · LymphomaNot yet recruitingPhase 2 / Phase 3NCT07917754

    A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)

    Merck Sharp & Dohme LLC · Locations not reported · Updated 2026-11-05

  • Heme · LymphomaRecruitingPhase 3NCT06091865

    A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

    Regeneron Pharmaceuticals · 195 locations · Updated 2026-11-04

  • Heme · LymphomaRecruitingPhase 3NCT05929222

    Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

    Fondazione Italiana Linfomi - ETS · 49 locations · Updated 2026-09-08

  • Heme · CLL, LymphomaRecruitingPhase 3NCT06319456

    A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

    Ascentage Pharma Group Inc. · 10 locations · Updated 2026-07-28

  • Heme · LymphomaRecruitingPhase 3NCT06911502

    A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

    Celgene · 160 locations · Updated 2026-05-20

  • Heme · LymphomaRecruitingPhase 3NCT04043494

    International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

    University Hospital Muenster · 228 locations · Updated 2026-05-06

  • Heme · LymphomaRecruitingPhase 2NCT06510361

    A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy

    Beth Israel Deaconess Medical Center · 3 locations · Updated 2026-11-12

  • Heme · LymphomaRecruitingPhase 2NCT06054776

    Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    City of Hope Medical Center · 1 locations · Updated 2026-11-03

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06520098

    A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    VA Office of Research and Development · 4 locations · Updated 2026-10-30

  • Heme · LymphomaRecruitingPhase 1 / Phase 2NCT05861050

    Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

    City of Hope Medical Center · 3 locations · Updated 2026-10-26

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07024706

    MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

    AstraZeneca · 47 locations · Updated 2026-10-23

  • Heme · LymphomaRecruitingPhase 2NCT06526793

    Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

    AstraZeneca · 94 locations · Updated 2026-10-14

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06918431

    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    City of Hope Medical Center · 8 locations · Updated 2026-10-13

  • Heme · LymphomaRecruitingPhase 2NCT06252675

    Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

    University of California, San Francisco · 4 locations · Updated 2026-10-01

  • Heme · LymphomaRecruitingPhase 2NCT07126236

    Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

    Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · 19 locations · Updated 2026-09-29

  • Heme · LymphomaRecruitingPhase 1 / Phase 2NCT06634589

    A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

    BeOne Medicines · 49 locations · Updated 2026-09-11

  • Heme · ALL, CLL, LymphomaNot yet recruitingPhase 2NCT07812246

    Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial

    City of Hope Medical Center · 3 locations · Updated 2026-09-10

  • Heme · LymphomaNot yet recruitingPhase 2NCT07502872

    TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

    Brown University · 1 locations · Updated 2026-09-01

  • Heme · LymphomaRecruitingPhase 1 / Phase 2NCT07284433

    Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

    AvenCell Therapeutics, Inc. · 13 locations · Updated 2026-08-28

  • Heme · LymphomaRecruitingPhase 2NCT06594939

    Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

    Medical College of Wisconsin · 1 locations · Updated 2026-08-25

  • Heme · AML, LymphomaNot yet recruitingPhase 1 / Phase 2NCT07749976

    GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors

    Vitruviae · Locations not reported · Updated 2026-08-06

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07526597

    Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors

    UNC Lineberger Comprehensive Cancer Center · 1 locations · Updated 2026-08-05

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07459608

    Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma

    Henan Cancer Hospital · 1 locations · Updated 2026-07-29

  • Heme · LymphomaRecruitingPhase 2NCT07082686

    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

    Beijing InnoCare Pharma Tech Co., Ltd. · 29 locations · Updated 2026-07-23

  • Heme · LymphomaRecruitingPhase 2NCT07719556

    Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)

    The First Affiliated Hospital with Nanjing Medical University · 2 locations · Updated 2026-07-22

  • Heme · LymphomaRecruitingPhase 2NCT06558604

    Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

    The Lymphoma Academic Research Organisation · 16 locations · Updated 2026-07-10

  • Heme · LymphomaRecruitingPhase 2NCT06854159

    Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

    University of California, Davis · 1 locations · Updated 2026-07-08

  • Heme · LymphomaNot yet recruitingPhase 2NCT07684950

    Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy

    Henan Cancer Hospital · 1 locations · Updated 2026-07-06

  • Heme · LymphomaRecruitingPhase 2NCT06905509

    Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

    University of California, Davis · 1 locations · Updated 2026-06-30

  • Heme · ALL, LymphomaRecruitingPhase 2NCT02877303

    Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-05-20

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07523555

    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

    Beijing Biotech · 1 locations · Updated 2026-04-13

  • Heme · ALL, LymphomaRecruitingPhase 1 / Phase 2NCT05674175

    Co-administration of CART22-65s and huCART19 for B-ALL

    Stephan Grupp MD PhD · 1 locations · Updated 2026-03-27

  • Heme · LymphomaRecruitingPhase 2NCT05800366

    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

    Jennifer Crombie, MD · 3 locations · Updated 2026-03-05

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07014917

    Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

    Zulfa Omer · 1 locations · Updated 2026-01-06

  • Heme · LymphomaRecruitingPhase 2NCT05260957

    CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

    Lazaros Lekakis · 1 locations · Updated 2025-12-31

  • Heme · LymphomaRecruitingPhase 2NCT07165769

    Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-18

  • Heme · ALL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07153068

    SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-15

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06978088

    LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

    Zulfa Omer · 1 locations · Updated 2025-08-14

  • Heme · LymphomaNot yet recruitingPhase 2NCT07122609

    Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Ruijin Hospital · 1 locations · Updated 2025-08-14

  • Heme · LymphomaRecruitingPhase 2NCT07106723

    Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-08-06

  • Heme · LymphomaNot yet recruitingPhase 1 / Phase 2NCT07020260

    The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

    Princess Maxima Center for Pediatric Oncology · 2 locations · Updated 2025-06-13

  • Heme · ALL, CLL, LymphomaRecruitingPhase 2NCT05281809

    Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    John Lister · 1 locations · Updated 2025-01-13

  • Heme · ALL, LymphomaRecruitingPhase 2NCT06742463

    VHAG in Treating R/R T-ALL/LBL

    First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-12-19

  • Heme · LymphomaNot yet recruitingPhase 2NCT06427213

    This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

    Henan Cancer Hospital · Locations not reported · Updated 2024-05-23

  • Heme · LymphomaNot yet recruitingPhase 2NCT06255704

    A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

    Shanxi Province Cancer Hospital · 1 locations · Updated 2024-02-13

  • Heme · LymphomaRecruitingPhase 2NCT05833763

    A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

    Australasian Leukaemia and Lymphoma Group · 2 locations · Updated 2024-01-08

  • Heme · LymphomaRecruitingPhase 2NCT05833893

    Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

    Chinese PLA General Hospital · 1 locations · Updated 2023-04-27

  • Heme · ALL, LymphomaRecruitingPhase 1NCT06173518

    A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    Autolus Limited · 15 locations · Updated 2026-11-13

  • Heme · ALL, LymphomaRecruitingPhase 1NCT06208735

    CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

    British Columbia Cancer Agency · 7 locations · Updated 2026-10-14

  • Heme · ALL, LymphomaRecruitingPhase 1NCT07350863

    U69-CART-Cells For R/R T-ALL

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-09-02

  • Heme · ALL, LymphomaRecruitingPhase 1NCT07586618

    First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

    Allterum Therapeutics, Inc · 7 locations · Updated 2026-09-01

  • Heme · ALL, LymphomaRecruitingNot reportedObservationalNCT06785818

    Long-term Follow up Local Registry Study of Kymriah in South Korea

    Novartis Pharmaceuticals · 18 locations · Updated 2026-07-30

  • Heme · Myeloma, LymphomaRecruitingEarly Phase 1NCT07101705

    An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-07-21

  • Heme · LymphomaNot yet recruitingEarly Phase 1NCT07670260

    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma

    Chinese PLA General Hospital · 1 locations · Updated 2026-06-26

  • Heme · CLL, LymphomaRecruitingPhase 1NCT04892277

    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

    Mayo Clinic · 1 locations · Updated 2026-06-09

  • Heme · ALL, LymphomaNot yet recruitingPhase 1NCT07539610

    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-04-20

  • Heme · LymphomaRecruitingNot reportedObservationalNCT05816850

    Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

    Fondazione Italiana Linfomi - ETS · 26 locations · Updated 2025-12-29

  • Heme · LymphomaNot yet recruitingPhase 1NCT07166549

    Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

    University Hospital, Basel, Switzerland · 1 locations · Updated 2025-12-24

  • Heme · CLL, LymphomaNot yet recruitingNot applicableNCT07286539

    Precision Physical Exercise for Personalized Onco-Hematology.

    University of Salamanca · Locations not reported · Updated 2025-12-16

  • Heme · ALL, LymphomaNot yet recruitingPhase 1NCT07234045

    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-11-18

  • Heme · LymphomaRecruitingNot reportedObservationalNCT04510766

    Tumor Molecular Profiling in Early Phase Clinical Trials

    Oncology Institute of Southern Switzerland · 1 locations · Updated 2025-11-18

  • Heme · LymphomaRecruitingNot applicableNCT07126678

    Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

    The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2025-08-17

  • Heme · ALL, LymphomaRecruitingNot applicableNCT06866873

    CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

    Hong Kong Children's Hospital · 1 locations · Updated 2025-03-10

  • Heme · LymphomaRecruitingNot reportedObservationalNCT06733987

    Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

    IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 locations · Updated 2024-12-13

  • Heme · LymphomaNot yet recruitingNot reportedObservationalNCT06651203

    Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study

    Assistance Publique - Hôpitaux de Paris · Locations not reported · Updated 2024-10-21

  • Heme · LymphomaRecruitingPhase 4NCT05518383

    B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

    Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2022-08-26

  • Heme · ALL, LymphomaRecruitingEarly Phase 1NCT04227015

    A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

    He Huang · 1 locations · Updated 2020-12-28

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.